ライフサイエンスコーパス: contrast enhancement

1 esions and central areas of necrosis without contrast enhancement.

2 d the first in vivo use of Eu(II) to provide contrast enhancement.

3 a core needle biopsy of lesions that undergo contrast enhancement.

4 rmine seven parameters characterizing tissue contrast enhancement.

5 tems, where it can perform such functions as contrast enhancement.

6 clearly colocalized with the initial site of contrast enhancement.

7 ogenous carotenoids with nonlinear PA and PT contrast enhancement.

8 gered, the gaseous phase provides ultrasound contrast enhancement.

9 derwent MRI examination before and after the contrast enhancement.

10 n LGGs was based on (18)F-FDG uptake and MRI contrast enhancement.

11 ties, but few options for genetic control of contrast enhancement.

12 tion of PML lesions by use of MRI, including contrast enhancement.

13 ncement, and abdomen-pelvis with intravenous contrast enhancement.

14 ed during the late hepatic arterial phase of contrast enhancement.

15 ly during the late hepatic arterial phase of contrast enhancement.

16 cts at high resolution by delayed myocardial contrast enhancement.

17 in vivo r1 values and afforded excellent MR contrast enhancement.

18 sociated with a "garland ring" of gadolinium contrast enhancement.

19 (BBB) breakdown revealed by gadolinium (Gd) contrast enhancement.

20 cortical networks, serving such functions as contrast enhancement.

21 indeterminism are motion artifacts and poor contrast enhancement.

22 eighted signal intensity, and rapid moderate contrast enhancement.

23 -weighted MR imaging demonstrated peripheral contrast enhancement.

24 characterised by restricted diffusion and no contrast enhancement.

25 lobal signal processing, such as large-scale contrast enhancement.

26 esions, a phase rim colocalized with initial contrast enhancement.

27 pe was defined by the presence or absence of contrast enhancement.

28 leaks showed significantly earlier mean peak contrast enhancement (0.28 second +/- 0.83) compared wit

29 nsity (27/32), T2 hyperintensity (25/32) and contrast enhancement (20/20).

30 as most often motion (74%), followed by poor contrast enhancement (40%).

31 BVs collocated with hypoxia (81.3%) and with contrast enhancement (46.5%).

32 n, patient medication, radiation protection, contrast enhancement, acquisition and reconstruction par

33 od volume [CBV]), and vascular permeability (contrast enhancement after gadolinium injection) were an

34 s potential magnetic resonance imaging (MRI) contrast enhancement agents.

35 -DTPA, and PIP-DOTA possess potential as MRI contrast enhancement agents.

36 Application of the contrast-enhancement algorithm significantly increased t

37 ry network were generated with custom motion contrast enhancement algorithms.

38 ial and also during the late venous phase of contrast-enhancement, also lower than the normal surroun

39 sitive, but not 1:1, correlation between MRI contrast enhancement and (89)Zr-bevacizumab uptake.

40 the lesion edge, seen on MRI as centripetal contrast enhancement and a colocalized phase rim.

41 le diverticula, thickened walls with showing contrast enhancement and adjacent jejunum in the left mi

42 hout the nervous system that often generates contrast enhancement and center-surround receptive field

43 Increased positive contrast enhancement and highly accelerated acquisition

44 ce, the nanofluorophores can increase kidney-contrast enhancement and imaging-time window by approxim

45 es significant background reduction and thus contrast enhancement and is demonstrated on quantum dot-

46 Tumor contrast enhancement and mass effect predicted activatio

47 Furthermore, they exhibit much stronger contrast enhancement and much longer blood retention tim

48 luding frontal location and lesser extent of contrast enhancement and necrosis), relates them to lowe

49 ably distinguish between common postsurgical contrast enhancement and orbital tumor recurrence, and t

50 ur, homogeneous-versus-heterogeneous signal, contrast enhancement and paramagnetic susceptibility eff

51 d of being a culprit lesion with both plaque contrast enhancement and plaque thickness were estimated

52 demonstrated a significant and sustained MRI contrast enhancement and probe accumulation in tumors wi

53 ium, and CT scanning factors associated with contrast enhancement and scan timing are presented and d

54 analysis of various factors associated with contrast enhancement and scan timing.

55 n vivo are currently limited by the moderate contrast enhancement and stability of T(1)-based MRET pr

56 se To determine the relationship between MRI contrast enhancement and the injected dose of gadopiclen

57 hy (MM-OCT) represents a new methodology for contrast enhancement and therapeutic interventions in mo

58 rameters (maximal lesion diameter, volume of contrast enhancement) and originating primary tumor.

59 without contrast enhancement, chest without contrast enhancement, and abdomen-pelvis with intravenou

60 tical vasogenic and cytotoxic edema, partial contrast enhancement, and hyperperfusion.

61 tic MRI patterns, especially the presence of contrast enhancement, and the subcortical location may h

62 esence of haemorrhage, restricted diffusion, contrast enhancement, and vasoconstriction are all compa

63 changes in tumor density or signal intensity/contrast enhancement, and/or [18F]-fluorodeoxyglucose po

64 se core and hyperintense rim with or without contrast enhancement; and (2) "Motor Neuron" pattern: a

65 sted by smart molecular labeling and dynamic contrast enhancement approaches that enable new types of

66 tional capabilities like targeting and image contrast enhancement are added to the nanoparticles.

67 ons in imaging features, such as necrosis or contrast enhancement, are common.

68 Dixon fat images, unaffected by the dynamic contrast-enhancement, are used to efficiently estimate r

69 etection by magnetic resonance imaging (MRI) contrast enhancement as well as targeted cancer cell the

70 ith a BA-to-lipid ratio of 25% exhibited 30% contrast enhancement at B1=4.7muT in vitro.

71 -six lesions were considered active owing to contrast enhancement at baseline; 37 lesions (66%) in 10

72 With use of fusion imaging, glioblastoma contrast enhancement at contrast-enhanced US (regarding

73 In contrast, VOIs of increased contrast enhancement at follow-up compared with baseline

74 successfully ablated if they demonstrated no contrast enhancement at follow-up computed tomography or

75 ast agents are promising as alternatives for contrast enhancement at T1-weighted MR imaging and have

76 rCBV up to the point of transformation, when contrast enhancement became apparent on T1-weighted imag

77 croscopic fluorescence imaging that provides contrast enhancement between normal and diseased tissue

78 ultimately induces a behaviorally expressed contrast enhancement between the two similar stimuli tha

79 aders, 0.05 mmol/kg of gadopiclenol improved contrast enhancement, border delineation, and visualizat

80 diologists visually and qualitatively scored contrast enhancement, border delineation, and visualizat

81 T2-weighted hyperintensity and contrast enhancement both yielded 100% sensitivity but a

82 t is also shown that the spatial location of contrast enhancement can be controlled via laser polariz

83 time assessment of tumor vascularity so that contrast enhancement can be identified regardless of its

84 We also demonstrate that Eu(II)-based contrast enhancement can be observed for hours in a mous

85 eactive blood-brain barrier alterations with contrast enhancement can mimic tumor progression.

86 The contrast enhancement capabilities in imaging and in diff

87 ond imaging with routine breath-hold delayed contrast-enhancement cardiovascular magnetic resonance (

88 can be rapidly detected by subsecond delayed contrast-enhancement cardiovascular magnetic resonance d

89 An ultrafast, delayed contrast-enhancement cardiovascular magnetic resonance t

90 und was judged semiquantitatively; low-grade contrast enhancement (CE) suggested its absence, and hig

91 The (18)F-FDG uptake pattern and MR imaging contrast enhancement (CE) varied by tumor type.

92 Beyond the leading edge of contrast enhancement cerebral perfusion varied, patients

93 mination types were evaluated: brain without contrast enhancement, chest without contrast enhancement

94 th pattern (chi2: P = 0.046) associated with contrast enhancement (chi2: P = 0.011).

95 otive photoacoustic imaging, with remarkable contrast enhancement compared with photoacoustic images

96 mage averaging, normalization, cryo-EM image contrast enhancement correction (CEC), histogram equaliz

97 r rows and the corresponding time lag in the contrast enhancement curves and was correlated with the

98 s than 1 minute and resulted in high-quality contrast enhancement curves both at rest and stress (mea

99 A Dynamic Contrast Enhancement (DCE) protocol was used to capture

100 graded from category 3 to 4 based on dynamic contrast enhancement (DCE) score of positive; 50.0%-66.7

101 RV delayed contrast enhancement (DCE) was found in 9 (39%) of 23 pa

102 The PIZ as characterized by delayed contrast-enhancement (DE)-MRI identifies patients suscep

103 iomaterials with built-in optical signal and contrast enhancement, demonstrated here with simultaneou

104 umbar spine, ill-defined paraspinal abnormal contrast enhancement, diffuse/homogeneous contrast enhan

105 Enhanced US modalities with intravenous contrast enhancement dramatically improve vascular imagi

106 2) retained sufficient Mn(2+) to demonstrate contrast enhancement during MEMRI.

107 To achieve consistent contrast enhancement during pulmonary CT angiography, th

108 a given patient weight to achieve desirable contrast enhancement during pulmonary CT angiography.

109 er ischemia was defined as reduced or absent contrast enhancement during the portal phase.

110 s usually a hypovascular lesion, showing low contrast-enhancement during the early arterial and also

111 es in overall charge of the complex modulate contrast enhancement, especially of the kidneys.

112 rent MPNSTs were examined for configuration, contrast enhancement, extent, and signal intensity in MR

113 To distinguish RCC subtypes based on contrast enhancement features of CT images.

114 Contrast enhancement features of renal masses were evalu

115 otocol design that are necessary to optimize contrast enhancement for common clinical CT applications

116 l A, protocol B yielded significantly higher contrast enhancement for the aorta (508.6 HU vs 221.5 HU

117 red during the pancreatic parenchymal phase: contrast enhancement for the aorta, the pancreas, and th

118 uirements for molecular imaging and targeted contrast enhancement for these modalities.

119 vo experiments achieve long-lasting positive-contrast enhancement for vascular MRI in rabbits.

120 Myocardial contrast enhancement from microbubbles characteristicall

121 pment difficult, and IONPs suitable for T(1) contrast enhancement have yet to make their way to clini

122 he CDC enables a quantitative description of contrast enhancement heterogeneity in lesions.

123 On late gadolinium contrast enhancement images, the size of infarction and

124 us density infiltrative hepatic mass with no contrast enhancement in 19 patients or thick-walled cyst

125 We could detect contrast enhancement in 41% (7 of 17) of the cases on th

126 It generates prominent contrast enhancement in aggressive MDA-MB-231 triple neg

127 f the blood-brain barrier as demonstrated by contrast enhancement in cerebral adrenoleukodystrophy an

128 tionally, those structures showed noticeable contrast enhancement in CT and MRI.

129 reparation parameters to elicit maximal CEST contrast enhancement in healthy fibroglandular breast ti

130 PA showed topical and wound interface contrast enhancement in human subjects after cataract su

131 e these nanoparticles, showing high negative-contrast enhancement in magnetic-resonance imaging (MRI)

132 x-ray mammography, characteristic pattern of contrast enhancement in MR examination or less strain in

133 ion of malignant progression than changes of contrast enhancement in MR imaging (accuracy, 81% vs. 63

134 signal intensity, milk duct appearance, and contrast enhancement in normal and tumor-containing brea

135 work suggests an important role for auditory contrast enhancement in normalization: preceding context

136 in plaque was evaluated as an acute, and non-contrast enhancement in plaque was evaluated as a chroni

137 Contrast enhancement in plaque was evaluated as an acute

138 function, first-pass perfusion, and delayed contrast enhancement in remote myocardium and microinfar

139 Contrast enhancement in sensory systems often relies on

140 ducts in seven, and rapid initial glandular contrast enhancement in seven.

141 re biocompatible and can produce significant contrast enhancement in T2-weighted MRI.

142 Intravascular contrast enhancement in the abdominal aorta and brachioc

143 The most common overall pattern was contrast enhancement in the border of the PML lesion wit

144 CLIO-VT750 FMT signal coregistered with contrast enhancement in the hypokinetic infarct on MRI.

145 nd that CREKA-Tris(Gd-DOTA)3 provides robust contrast enhancement in the metastatic tumours and enabl

146 Median contrast enhancement in the pulmonary artery was 8.9% lo

147 ending aorta achieved a significantly higher contrast enhancement in the pulmonary trunk with a mean

148 ombination of electronic cleansing and bowel contrast enhancement in the range of 300-500 HU results

149 locus for mechanisms of light adaptation and contrast enhancement in the retina.

150 monstrates at least a 2-second delay in peak contrast enhancement in the right or left vertebral arte

151 ) showed persistent (up to at least 2 hours) contrast enhancement in the vascular branches (Mn(2+) co

152 these nanoconjugates shows more than 60-fold contrast enhancement in tumor visualization relative to

153 Neovascular contrast enhancement in Vx2 tumors (at 14 days) was 5.4%

154 Contrast enhancement increased with body weight (P < .01

155 thyltransferase promoter methylation status, contrast enhancement, initial treatment, and TTP(min) sh

156 th interval period), we found progression of contrast enhancement into the formerly hypoperfused peri

157 ant increases in rCBV up to 12 months before contrast enhancement is apparent on T1-weighted MR image

158 Strong tumour contrast enhancement is consistently observed in other t

159 Contrast enhancement is demonstrated first with colloida

160 g window width and window center higher when contrast enhancement is lower and vice versa.

161 The recognition that contrast enhancement is nonspecific and may not always b

162 n of cancer in situations where pathological contrast enhancement is not observed.

163 due to hypercellular metastases, even if no contrast enhancement is observed.

164 In non-human primates (NHP), contrast enhancement is possible using monocrystalline i

165 Contrast enhancement is the most common earliest sign of

166 power or color Doppler US performed without contrast enhancement, is better able to depict and disti

167 The PCA-based method can quantify contrast enhancement kinetics of BP semiautomatically, a

168 This might influence the interpretation of contrast enhancement kinetics of breast lesions and curr

169 complex, interrelated parameters influencing contrast enhancement make the development difficult, and

170 of their fluorescence allows for substantial contrast enhancement, making PAiRFPs advantageous over p

171 calization of brain tumors and, by virtue of contrast enhancement, malignant ones.

172 tener's perception, and which follows from a contrast enhancement model.

173 Contrast enhancement MRI detected six of seven (86%) ani

174 Contrast enhancement MRI using Gd-DTPA provides a method

175 We employed contrast enhancement MRI with Gd-DTPA to detect HT in a

176 rated into 2 groups, those performed without contrast enhancement (n = 12,475) and those performed wi

177 ility can be used for object identification, contrast enhancement, navigation, and communication thro

178 Six MR imaging features-contrast enhancement, necrosis, contrast-to-necrosis rat

179 ging findings such as mass effect, swelling, contrast enhancement, new perivascular T2 lesions and si

180 ) from precontrast MRI and normalized marrow contrast enhancement (NMCE) following intravenous admini

181 contrast agents generates a strong positive contrast enhancement of >1 order of magnitude.

182 arkfield sensing and imaging (observed image contrast enhancement of 27 dB for the first SWEDA).

183 icantly hinder immunomicelles from providing contrast enhancement of atherosclerotic vessels in vivo.

184 rovide insight into the physiologic basis of contrast enhancement of DCIS lesions on DCE MR images: G

185 were used for therapeutic targeting and MRI contrast enhancement of experimental glioblastoma, both

186 Contrast enhancement of gadolinium-enhanced T1-weighted

187 of Fe(2+)-PyC3A generates strong, selective contrast enhancement of inflamed pancreatic tissue in a

188 Contrast enhancement of intracranial atherosclerotic pla

189 status contribute to a large variability in contrast enhancement of normal breast parenchyma.

190 or for assessing tissue viability from late contrast enhancement of scar tissue.

191 ed optic nerve enlargement in 3 patients and contrast enhancement of the optic nerve in all patients.

192 ovascular but provided less than half of the contrast enhancement of the targeted agent.

193 Angiotensin II infusion increased contrast enhancement of the tumor and distal liver vesse

194 lioblastoma tumors can provide selective MRI contrast enhancement of tumor cells and targeted therapy

195 n of the vertebral body, focal/heterogeneous contrast enhancement of vertebral bodies, heterogeneous

196 al contrast enhancement, diffuse/homogeneous contrast enhancement of vertebral bodies, low-grade dest

197 By contrast, enhancement of adrenergic signaling by adminis

198 In contrast, enhancement of neural activity by whisker stim

199 In contrast, enhancement of priming is a good candidate for

200 By contrast, enhancement of the severity of the Oy1-N1989 p

201 nse rates, as defined by a rapid decrease in contrast enhancement on CT/MRI that occurs within days o

202 Contrast enhancement on imaging is highly sensitive at t

203 her tumor grade is typically associated with contrast enhancement on magnetic resonance imaging.

204 with bevacizumab may result in a decrease in contrast enhancement on MRI despite tumor progression.

205 The ratio of contrast enhancement on MRI to normalized PET probe upta

206 All masses revealed homogeneous contrast enhancement on postcontrast T1-weighted images.

207 nce-status score, and presence or absence of contrast enhancement on preoperative images.

208 e images show that B-GQDs induce significant contrast enhancement on the heart, liver, spleen, and ki

209 the treatment, nor in HER2 expression or in contrast-enhancement on MRI between the responders and n

210 inflammatory responses from other sources of contrast-enhancement on MRI.

211 CT tumor density, contrast enhancement, or MRI characteristics appear more

212 were analyzed: dimension, degree and type of contrast enhancement, outlines of lesions, presence of i

213 section thickness of 128 microm and an 8.9 x contrast enhancement over uniform illumination.

214 class GBM had significantly lower levels of contrast enhancement (P = .02) than other subtypes, whil

215 The pharmacokinetic contrast enhancement parameters of tumors were compared

216 nd functional ADC values as well as arterial contrast enhancement parameters showed non-significant a

217 SUV and functional ADCs, as well as arterial contrast enhancement parameters, showed nonsignificant a

218 IRM images, well-defined paraspinal abnormal contrast enhancement, paraspinal and epidural abscesses,

219 The qualitative analysis of contrast enhancement pattern demonstrated a similar dist

220 In one patient, the contrast enhancement pattern differed between the two mo

221 ratio (CNR) of the lesions, as well as their contrast enhancement patterns (ring, heterogeneous, homo

222 resholds at each combination of ROI size and contrast enhancement phase were calculated, and receiver

223 ctor CT image acquisition during two or more contrast enhancement phases.

224 th silica gel to simulate soft tissues, with contrast enhancement pigments added to simulate differen

225 Purpose To compare intravascular contrast enhancement produced by the manganese-based mag

226 nship between regional ammonia retention and contrast enhancement (R=-0.93, P<0.001).

227 An inverse linear relationship between the contrast enhancement rate constant during imaging and th

228 fusion on BBB opening, we calculated the MRI contrast enhancement rate.

229 For quantitative analysis, contrast enhancement ratio (CER), lesion-to-liver contra

230 -2.74 for the aorta-based corrected relative contrast enhancement ratio and a cutoff of 2.63-2.76 for

231 ging, while SNR was higher (11.6 vs 5.6) and contrast enhancement ratio was lower (1.1 vs 1.5, P = .0

232 r fossa tumors, additional use of the CBF-to-contrast enhancement ratio yielded sensitivity and speci

233 more, a cutoff of 2.42-2.72 for the relative contrast enhancement ratio, a cutoff of 2.59-2.74 for th

234 t scores, signal-to-noise ratios (SNRs), and contrast enhancement ratios were derived.

235 act thickness, 1.6 vs 2.4 mm, P < .001), and contrast enhancement ratios were similar.

236 Scanning the aortic reference with peak contrast enhancement reduces variability sufficiently to

237 the volumes of the high CBV regions and the contrast-enhancement regions.

238 re, Glu222 decarboxylation yields a 100-fold contrast enhancement relative to wild-type GFP (WT).

239 imilar to the pattern seen at PML-IRIS, with contrast enhancement representing the most frequent sign

240 Reflecting the interpatient differences in contrast enhancement, resected tumors exhibited dramatic

241 ) indicate signal intensity before and after contrast enhancement, respectively.

242 of the models, simulated aortic and hepatic contrast-enhancement results throughout the models were

243 The contrast-enhancement results were in agreement with resu

244 ft is both necessary and sufficient to yield contrast enhancement revealing mesoscopic proximity of l

245 Parameters of contrast enhancement, risk of aggressiveness, and nodule

246 arly challenging in neuro-oncology for which contrast enhancement serves as an imperfect surrogate fo

247 Grade of contrast enhancement showed predictive value in classify

248 igher baseline T1 SI tended to have a higher contrast enhancement slope.

249 ing; and-before and after gadolinium chelate contrast enhancement-T1-weighted 3-dimensional spoiled g

250 omic features (T1 weighted, T1 weighted with contrast enhancement, T2 weighted, and fluid-attenuated

251 vealing a mechanism for nociceptive temporal contrast enhancement (TCE).

252 Culprit plaques had a higher degree of contrast enhancement than did nonculprit plaques (25.9%

253 nt and entheseal changes, but with much less contrast enhancement than in PsA and less bone involveme

254 Clear cell RCC (ccRCC) showed more intense contrast enhancement than other RCC subtypes.

255 significant T1 relaxation shortening and MRI contrast enhancement that is blocked by particle formati

256 In those patients with contrast enhancement, the enhancement was present in the

257 quantitative assessment evaluated the aortic contrast enhancement, the respiratory hepatic translatio

258 To study dynamic contrast enhancement, three mice with 4T1 tumors were im

259 s enable multiple modes of imaging, and that contrast enhancement through aggregation permits their u

260 Contrast enhancement-time curves were near-automatically

261 rast-enhanced MR angiography with comparable contrast enhancement to gadolinium-based agents and may

262 no gold particles) almost completely blocked contrast enhancement to pretreatment levels, similar to

263 e enhanced US modalities include intravenous contrast enhancement, to better visualize areas with inc

264 icularly phase imaging combined with dynamic contrast enhancement, to provide new insights in acute M

265 rected AV and aorta-based corrected relative contrast enhancement values in the corticomedullary phas

266 although anti-VEGF agents may decrease tumor contrast-enhancement, vascularity, and edema, the mechan

267 Furthermore, gadolinium contrast-enhancement volumes on MRI (Gd-volume) and tumo

268 Contrast enhancement was 9.3% in the lowest quintile and

269 Significant OCT contrast enhancement was achieved with improved visualiz

270 The MR contrast enhancement was also demonstrated in vivo using

271 In these patients, grade 2 contrast enhancement was associated with culprit plaques

272 Contrast enhancement was better with SHI than with power

273 f the pituitary infundibulum), and degree of contrast enhancement was calculated.

274 Plaque contrast enhancement was categorized on BB MR images (gr

275 Contrast enhancement was evaluated using a semi-quantita

276 The contrast enhancement was measured in inflamed synovial t

277 Contrast enhancement was measured in the main pulmonary

278 Late contrast enhancement was observed in only 2 patients wit

279 Comparable contrast enhancement was obtained with direct infusions

280 In previous studies, the contrast enhancement was predicted to depend on the rigi

281 Contrast enhancement was robust only when compensation w

282 In six patients, no late contrast enhancement was seen, whereas all patients had

283 f different predictors of T1 baseline SI and contrast enhancement was studied by using random-effects

284 Contrast enhancement was the most common imaging sign su

285 Late contrast enhancement was used to detect areas of myocard

286 matinib in most cases a decrease in size and contrast enhancement were observed; the outlines of lesi

287 the most perfused area of each neoplasm and contrast enhancement were quantified with a semiquantita

288 TIRM and T1-weighted images with and without contrast enhancement were subject to assessment in coron

289 Greater contrast enhancements were seen for MRI agents that were

290 NPs showed -89.1 +/- 5.7% and -0.9 +/- 0.2% contrast enhancement, whereas in in vivo study, it is fo

291 antification of the T1 relaxation time after contrast enhancement, which can be sensitive to equilibr

292 ed by transmission electron microscopy after contrast enhancement with cationic dye fixation.

293 Conclusion Glioblastoma contrast enhancement with contrast-enhanced US is superi

294 Dynamic contrast enhancement with ICG was possible.

295 d platform achieves a substantially improved contrast enhancement with minimal background signal and

296 is of simulation-driven optimization for APT contrast enhancement with the CEST effect quantified by

297 ar appearance in the early arterial phase of contrast-enhancement, with a dynamic enhancement pattern

298 h DSC MR imaging, which revealed progressive contrast enhancement within the radiation field.

299 The time delay between contrast enhancement within the stent lumen and the endo

300 eletion (absent vs present vs undetermined), contrast enhancement (yes vs no), age (<40 vs >/=40 year